Eli Lilly and Company have released the latest results from one of the new drugs that are trying to reduce Alzheimer’s dementia and the results look promising. The drug is called donanemab and the a study, called the TRAILBLAZER-ALZ study, was published in the New England Journal of Medicine Saturday.
“This is the first late study in Alzheimer’s disease to meet its key termination point at the main study. Donanemab has the potential to be a very important treatment for Alzheimer’s disease,” he said in a statement Daniel Skovronsky , MD, Ph.D. , Lilly ‘s chief scientific officer and president of Lilly Research Laboratories.
“We were pleased to see not only a slowing of cognitive decline and function, but also a major cleansing of amyloid plagues and a slowing of the spread of tau pathology. We are grateful to the patients, carers, and researchers who took part in this landmark study. “
The study followed 257 patients with early Alzheimer’s disease, 131 of whom received sinanemab, and 126 of whom received placebo. The results showed that 40 percent of participants treated with the new drug achieved amyloid negativity as early as six months after starting treatment and 68 percent achieved the same target by 18 months.
“A key finding of the results from the TRAILBLAZER-ALZ study is that donanemab not only significantly reduced the amount of amyloid deposition in these patients but also delayed the clinical progression of the disease. suggest that this could be a disease modification. We believe that these amyloid and tau imaging data lay the foundation for the treatment of Alzheimer ‘s disease based on detailed treatment, “said Liana G. Apostolova, MD, M.Sc ., FAAN, Indiana University (IU) Distinguished Professor and Professor Barbara and Peer Baekgaard in Alzheimer’s Disease. Research at IU School of Medicine.
If you or someone you want to see if they qualify for a test, you can visit the website.